Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (1-10 of 251) with videos related to

Pageof 26
Sort By:
Expert Opinion on Pharmacotherapy|March 12, 2004
Arsenic trioxide for the treatment of myelodysplastic syndromesNorbert Vey
Therapeutic Advances in Hematology|March 28, 2020
Low-intensity regimens <i>versus</i> standard-intensity induction strategies in acute myeloid leukemiaNorbert Vey
Interdisciplinary Topics in Gerontology|March 19, 2013
Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?Norbert Vey
Expert Opinion on Investigational Drugs|January 4, 2011
Vorinostat in acute myeloid leukemia and myelodysplastic syndromesThomas Prebet, Norbert Vey
Expert Opinion on Pharmacotherapy|February 19, 2010
Laromustine (cloretazine)Norbert Vey, Frank Giles
La Revue Du Praticien|March 24, 2011
[Current management of myelodysplastic syndromes]Norbert Vey, Aude Charbonnier
Expert Review of Anticancer Therapy|March 1, 2006
Cloretazine for the treatment of acute myeloid leukemiaNorbert Vey, Frank Giles
Current Oncology Reports|January 25, 2020
Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia TransformationMarie Anne Hospital, Norbert Vey
Critical Reviews in Oncology/Hematology|February 1, 2022
Diagnosis and treatment of therapy-related acute myeloid leukemiaStephen A Strickland, Norbert Vey
Medecine Sciences : M/S|September 2, 2011
[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?]Hassiba Chaib, Thomas Prébet, Norbert Vey, et al.
Pageof 26

Showing results (1-10 of 251) with videos related to

Sort By:
Pageof 26
Expert Opinion on Pharmacotherapy|March 12, 2004
Arsenic trioxide for the treatment of myelodysplastic syndromesNorbert Vey
Therapeutic Advances in Hematology|March 28, 2020
Low-intensity regimens <i>versus</i> standard-intensity induction strategies in acute myeloid leukemiaNorbert Vey
Interdisciplinary Topics in Gerontology|March 19, 2013
Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?Norbert Vey
Expert Opinion on Investigational Drugs|January 4, 2011
Vorinostat in acute myeloid leukemia and myelodysplastic syndromesThomas Prebet, Norbert Vey
Expert Opinion on Pharmacotherapy|February 19, 2010
Laromustine (cloretazine)Norbert Vey, Frank Giles
La Revue Du Praticien|March 24, 2011
[Current management of myelodysplastic syndromes]Norbert Vey, Aude Charbonnier
Expert Review of Anticancer Therapy|March 1, 2006
Cloretazine for the treatment of acute myeloid leukemiaNorbert Vey, Frank Giles
Current Oncology Reports|January 25, 2020
Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia TransformationMarie Anne Hospital, Norbert Vey
Critical Reviews in Oncology/Hematology|February 1, 2022
Diagnosis and treatment of therapy-related acute myeloid leukemiaStephen A Strickland, Norbert Vey
Medecine Sciences : M/S|September 2, 2011
[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?]Hassiba Chaib, Thomas Prébet, Norbert Vey, et al.
Pageof 26